AC Immune SA Forecasted to Post Q3 2017 Earnings of ($0.31) Per Share (ACIU)
AC Immune SA (NASDAQ:ACIU) – Equities research analysts at Jefferies Group issued their Q3 2017 earnings estimates for shares of AC Immune SA in a research report issued to clients and investors on Monday. Jefferies Group analyst P. Welford anticipates that the company will post earnings of ($0.31) per share for the quarter. Jefferies Group also issued estimates for AC Immune SA’s Q4 2017 earnings at ($0.10) EPS, FY2017 earnings at ($0.73) EPS, FY2018 earnings at ($0.94) EPS, FY2019 earnings at ($1.25) EPS, FY2020 earnings at ($1.35) EPS and FY2021 earnings at ($0.31) EPS.
ILLEGAL ACTIVITY WARNING: This report was reported by Watch List News and is the sole property of of Watch List News. If you are viewing this report on another site, it was stolen and republished in violation of US & international copyright and trademark legislation. The correct version of this report can be accessed at https://www.watchlistnews.com/ac-immune-sa-forecasted-to-post-q3-2017-earnings-of-0-31-per-share-aciu/1493961.html.
ACIU has been the topic of several other research reports. Zacks Investment Research downgraded AC Immune SA from a “hold” rating to a “sell” rating in a report on Thursday, July 20th. Credit Suisse Group set a $18.00 price objective on AC Immune SA and gave the stock a “buy” rating in a report on Wednesday, May 31st.
Shares of AC Immune SA (ACIU) opened at 7.19 on Wednesday. AC Immune SA has a 1-year low of $6.03 and a 1-year high of $19.97. The firm’s market capitalization is $409.27 million. The firm’s 50 day moving average is $8.02 and its 200 day moving average is $9.83.
A number of institutional investors have recently added to or reduced their stakes in ACIU. Goldman Sachs Group Inc. acquired a new position in AC Immune SA during the second quarter valued at $127,000. Victory Capital Management Inc. boosted its position in AC Immune SA by 78.4% in the first quarter. Victory Capital Management Inc. now owns 26,757 shares of the company’s stock valued at $277,000 after buying an additional 11,757 shares during the period. Monashee Investment Management LLC boosted its position in AC Immune SA by 74.7% in the first quarter. Monashee Investment Management LLC now owns 30,000 shares of the company’s stock valued at $311,000 after buying an additional 12,832 shares during the period. Finally, Cohen Lawrence B acquired a new position in AC Immune SA during the second quarter valued at $297,000. 18.34% of the stock is currently owned by institutional investors.
AC Immune SA Company Profile
AC Immune Ltd is a Switzerland-based company engaged in the medical biotechnology sector. It develops treatments for Alzheimer’s and other neurodegenerative diseases, such as Down syndrome, glaucoma and Parkinson’s, and focuses on producing therapeutic and diagnostic product candidates, using SupraAntigen and Morphomer technology platforms.
Receive News & Ratings for AC Immune SA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AC Immune SA and related companies with Analyst Ratings Network's FREE daily email newsletter.